ZBIO — Zenas BioPharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1953926 ·
Last close
$27.75
Market Cap
$1.88B
52W High
$44.60
52W Low
$13.50
ADV30
512,515
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 10,000,000 | — | -75,909,000 | -108,923,000 | 675,216,000 | 177,778,000 | 462,908,000 |
| Jun 2026 | 1,000,000 | — | -77,659,000 | -111,456,000 | 701,690,000 | 196,577,000 | 454,593,000 |
| Mar 2026 | 0 | — | -77,350,000 | -80,987,000 | 747,682,000 | 500,224,000 | 411,853,000 |
| Dec 2025 | 0 | — | -71,312,000 | -240,442,000 | 383,640,000 | 110,641,000 | 141,496,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-242,831,000
Investing CF
$-368,666,000
Financing CF
$673,591,000
CapEx
$-65,002,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.42
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,066,494,000
Inventory
—
Receivables
—
ST Investments
$446,549,000
EBIT TTM
$-503,466,000
Pretax Income TTM
$-541,539,000
Interest Exp TTM
$29,832,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,000,000
EBITDA
$-273,870,016
Free Cash Flow
$-211,391,632
Enterprise Value
$1,509,664,512
Total Cash
$643,126,016
Total Debt
$297,860,992
Shares Out
67,817,793
Trailing EPS
$-10.08
Book Value
$4.44
ROE
-199.0%
ROA
-34.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 10,000,000 | -211,385,000 | -377,737,000 | 383,640,000 | 141,496,000 | 242,144,000 | -172,333,000 |
| Dec 2024 | 5,000,000 | -163,888,000 | -156,988,000 | 369,968,000 | 57,510,000 | 312,458,000 | -119,674,000 |
| Dec 2023 | 50,000,000 | -27,147,000 | -37,124,000 | 68,180,000 | 293,901,000 | -225,721,000 | -30,529,000 |
| Dec 2022 | 0 | -75,199,000 | -119,282,000 | 74,579,000 | 266,865,000 | -192,286,000 | -65,652,000 |
TTM Snapshot
Revenues TTM
$4,018,000
NetIncome TTM
$-484,384,000
OpCashFlow TTM
—
Assets (Latest)
$701,690,000
Forward EPS
$-4.66
Max Pain — expiry 2027-01-15
max pain strike: $20.00 · spot: $26.42 · call oi: 1,026 · put oi: 2
Expected Move to 2027-01-15:
±$11.43
(43.26%) —
implied range
$14.99 –
$37.85
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HMDCF | HUTCHMED (China) Ltd | $1.88B | $2.16 | — |
| VERA | Vera Therapeutics, Inc. | $1.89B | $26.20 | — |
| SEPN | Septerna, Inc. | $1.90B | $40.02 | — |
| TRVI | Trevi Therapeutics, Inc. | $1.93B | $13.51 | — |
| ETON | Eton Pharmaceuticals, Inc. | $1.84B | $63.65 | — |
News headlines (Yahoo Finance, 1h cache)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-18 21:15 · Yahoo
Zenas BioPharma Launches The Distance Between Platform to Bring Greater Visibility to the Hidden Burden of IgG4-Related Disease
2026-11-17 12:00 · Yahoo
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference
2026-11-09 12:00 · Yahoo
Zenas BioPharma (ZBIO) After Third Quarter Losses Still Carries An Undervalued Narrative
2026-11-07 06:11 · Yahoo
Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 12:00 · Yahoo
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears
2026-10-30 15:14 · Yahoo
Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know
2026-10-23 12:55 · Yahoo
Zenas BioPharma Stock Gains Attention After Long Term Trial Data
2026-10-21 00:17 · Yahoo
Zenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data Release
2026-10-13 08:18 · Yahoo
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
2026-10-12 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.